Evidence map›Paper›PMID 34904631›Full record

ArticleBioscience reports2022

Regucalcin ameliorates doxorubicin-induced cytotoxicity in Cos-7 kidney cells and translocates from the nucleus to the mitochondria.

Noor A Mohammed, Israa J Hakeem, Nikolas Hodges, Francesco Michelangeli

Open access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Noor A MohammedSchool of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, U.K.
Israa J HakeemSchool of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, U.K.
Nikolas HodgesSchool of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, U.K.
Francesco MichelangeliFaculty of Medicine, Dentistry and Life Sciences, University of Chester, Parkgate Rd, Chester, CH1 4BJ, U.K.ORCID 0000-0002-4878-046X
University of Birmingham · GBUniversity of Chester · GBUniversity of Duhok · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (DOX) is a potent anticancer drug, which can have unwanted side-effects such as cardiac and kidney toxicity. A detailed investigation was undertaken of the acute cytotoxic mechanisms of DOX on kidney cells, using Cos-7 cells as kidney cell model. Cos-7 cells were exposed to DOX for a period of 24 h over a range of concentrations, and the LC50 was determined to be 7 µM. Further investigations showed that cell death was mainly via apoptosis involving Ca2+ and caspase 9, in addition to autophagy. Regucalcin (RGN), a cytoprotective protein found mainly in liver and kidney tissues, was overexpressed in Cos-7 cells and shown to protect against DOX-induced cell death. Subcellular localization studies in Cos-7 cells showed RGN to be strongly correlated with the nucleus. However, upon treatment with DOX for 4 h, which induced membrane blebbing in some cells, the localization appeared to be correlated more with the mitochondria in these cells. It is yet to be determined whether this translocation is part of the cytoprotective mechanism or a consequence of chemically induced cell stress.

Indexed as

Active Transport, Cell NucleusAnimalsAntibiotics, AntineoplasticApoptosisAutophagyCalcium-Binding ProteinsChlorocebus aethiopsCOS CellsDoxorubicinIntracellular Signaling Peptides and ProteinsKidneyKidney DiseasesMitochondriaSignal TransductionTime FactorsAntibiotics, AntineoplasticCalcium-Binding ProteinsDoxorubicinIntracellular Signaling Peptides and ProteinsRGN protein, humanapoptosiscalcium signallingcolocalizationnecrosisregucalcin

Identifiers

PMID34904631
PMCPMC8738856
OpenAlexW4200147142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.